NCT06396858 - Anti-inflammatory and Anti-thrombotic Therapy With colcHicine and Low Dose Rivaroxaban for Major Adverse Cardiovascular Events Reduction in Ischemic Stroke | Biotech Hunter

Enrollment

4,500

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

August 31, 2026

Study Completion Date

December 31, 2026

Conditions

Ischemic Stroke

Interventions

DRUG

Rivaroxaban 2.5 Mg Oral Tablet

Patients will receive one tablet, per oral or orogastric route, twice a day, for a maximum of 12 months.

DRUG

Colchicine 0.5 MG

Patients will receive one tablet, per oral or orogastric route, once a day, for a maximum of 12 months.

DRUG

Placebo Rivaroxaban

Patients will receive one tablet, per oral or orogastric route, twice a day, for a maximum of 12 months.

DRUG

Placebo Colchicine

Patients will receive one tablet, per oral or orogastric route, once a day, for a maximum of 12 months.